Phaseline

Targets › BTN1A1

BTN1A1 (Butyrophilin subfamily 1 member A1): drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Mar 2027.

May function in the secretion of milk-fat droplets. May act as a specific membrane-associated receptor for the association of cytoplasmic droplets with the apical plasma membrane (By similarity). (UniProt, Q13410)

Open in Phaseline: the race on BTN1A1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
STCubeNelmastobart
BTN1A1 agonist
BTN1A1Phase 2Non Small Cell Lung Cancer; Metastatic Colorectal Cancer (CRC)Mar 2027

Conditions

Non Small Cell Lung Cancer (1) Metastatic Colorectal Cancer (CRC) (1)

Modalities

antibody (1)

Companies

STCube (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.